SCHEMBL9952525

SCHEMBL9952525

CNC(=O)c1c(-c2ccccc2)c(C(C)NC(=O)OC(C)(C)C)nc2ncccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.39
PIK3CD O00329 3/20 0.39
PIK3CA P42336 3/20 0.39
PIK3CB P42338 3/20 0.39
PIK3CG P48736 3/20 0.39
CYP3A4 P08684 3/20 0.39
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
LIPG Q9Y5X9 1/20 0.35
METAP1 P53582 1/20 0.35
CTSK P43235 3/20 0.35
MAPT P10636 1/20 0.35
ATM Q13315 1/20 0.35
CTSS P25774 1/20 0.35
SSTR3 P32745 1/20 0.35
PPARA Q07869 2/20 0.34
PPARG P37231 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9958800 0.91 DHODH (0.46) DHODHCYP3A4MEN1NPC1GAA
SCHEMBL9959948 0.91 PIK3CD (0.41) DHODHPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3775458 0.87 MEN1 (0.44) PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4
SCHEMBL9958978 0.87 DHODH (0.46) DHODHPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL1995280 0.85 CYP3A4 (0.39) PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4
SCHEMBL9958921 0.83 DHODH (0.40) DHODHPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3778054 0.82 PIK3CD (0.40) PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4
SCHEMBL10079336 0.81 DHODH (0.46) DHODHPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3777865 0.80 PIK3CD (0.57) DHODHPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL9959801 0.78 PIK3CD (0.46) DHODHPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2013-10-30 EP disclosed
US-20130267526-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN, INC. (CA) 2013-10-10 US disclosed
US-20130267526-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN, INC. (CA) 2013-10-10 US disclosed
US-20130267526-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN, INC. (CA) 2013-10-10 US disclosed
WO-2012087784-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-06-28 WO disclosed
WO-2012087784-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267526-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 DHODH 2700/4885PIK3CD 25/4885PIK3CA 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.